Can minimal residual disease be used to tailor therapy duration for chronic lymphocytic leukemia patients?

INTRODUCTION: Undetectable minimal residual disease (uMRD) has emerged as a critical prognostic and potentially predictive biomarker in chronic lymphocytic leukemia (CLL), particularly in venetoclax-based time-limited regimens. AREAS COVERED: Clinica…

Preview only. Read the full abstract at the source